Hematologic effects of inactivating the Ras processing enzyme Rce1

Blood

Volumn 101, Issue 6, 2003, Pages 2250-2252

  Aiyagari, Abigail L ^a   Taylor, Brigit R ^a   Aurora, Vikas ^a   Young, Stephen G ^a   Shannon, Kevin M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEMBRANE ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEINASE; RAS PROTEIN; RCE1 ENDOPROTEASE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL POPULATION; CONTROLLED STUDY; DRUG DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INACTIVATION; FEMALE; FETUS LIVER; GENE MUTATION; HEMATOPOIESIS; HOMOZYGOTE; IRRADIATION; LIVER CELL; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN TARGETING; RECIPIENT;

EID: 0037443394     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2250     Document Type: Article

References (22)

1. Bourne HR, Sanders DA, McCormick F. The GT-Pase superfamily: a conserved switch for diverse cell functions. Nature. 1990;348:125-132.
2. Bourne HR, Sanders DA, McCormick F. The GT-Pase superfamily: conserved structure and molecular mechanism. Nature. 1991;349:117-127.
3. Boguski M, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643-653.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
5. Rodenhuis S. ras and human tumors. Semin Cancer Biol. 1992;3:241-247.
6. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;18:307-313.
7. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nat Genet. 1996;12:144-148.
8. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
9. Gibbs JB, Qliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol. 1997;37:143-166.
10. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2000; 19:6584-6593.
11. Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol. 2002;9:308-315.
12. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995;1:792-797.
13. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
14. Omer CA, Chen Z, Diehl RE, et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 2000;60:2680-2688.
15. Kim E, Ambroziak P, Otto JC, et al. Disruption of the mouse Rcel gene results in defective ras processing and mislocalization of ras within cells. J Biol Chem. 1999;274:8383-8390.
16. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195.
17. Haneline LS, Gebbert TA, Raman R, et al. Loss of FancC function results in a decrease in FancC-/hematopoietic stem cell repopulating ability. Blood. 1999;94:1-8.
18. Bollag G, Adler F, elMasry N, et al. Biochemical characterization of a novel KRAS insertional mutation from a human leukemia. J Biol Chem. 1996;273:32491-32494.
19. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31-36.
20. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science. 1993;260:1524-1527.
21. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001;29:25-33.
22. Bergo MO, Ambroziak P, Gregory C, et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol. 2002;22:171-181.